Imacent
Generic Name
Imatinib
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| imacent 100 mg tablet | ৳ 100.00 | ৳ 1,000.00 |
| imacent 400 mg tablet | ৳ 300.00 | ৳ 1,800.00 |
Description
Overview of the medicine
Imacent (Imatinib) is a tyrosine kinase inhibitor used to treat various types of cancer, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and gastrointestinal stromal tumors (GIST). It works by blocking the activity of abnormal proteins that signal cancer cells to multiply.
Uses & Indications
Dosage
Adults
CML (chronic phase): 400 mg orally once daily. GIST: 400 mg orally once daily. May vary based on indication and patient response.
Elderly
No specific dose adjustments required based on age alone, but monitor closely.
Renal_impairment
Consider starting with 300 mg daily for severe renal impairment; monitor closely.
How to Take
Take orally with a meal and a large glass of water to minimize gastrointestinal irritation. Do not crush or cut tablets.
Mechanism of Action
Imatinib selectively inhibits the Bcr-Abl tyrosine kinase, the constitutively activated enzyme implicated in CML and some ALL. It also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, both of which are involved in GIST pathogenesis.
Pharmacokinetics
Onset
Peak plasma concentrations achieved within 2-4 hours.
Excretion
Mainly via feces (68%) and urine (13%) as imatinib and its metabolites.
Half life
Approximately 18 hours for imatinib and 40 hours for its main active metabolite.
Absorption
Well absorbed orally, bioavailability approx. 98%.
Metabolism
Primarily metabolized by CYP3A4 to its main active metabolite (N-demethylated piperazine derivative).
Side Effects
Contraindications
- •Hypersensitivity to imatinib or any excipients.
Drug Interactions
Warfarin
Increased bleeding risk due to altered metabolism. Monitor INR closely.
CYP3A4 inducers
May decrease imatinib plasma concentrations, reducing efficacy. Avoid concomitant use.
CYP3A4 inhibitors
May increase imatinib plasma concentrations, increasing risk of side effects. Use with caution.
Storage
Store below 30°C in a dry place, away from light. Keep out of reach of children.
Overdose
Overdose symptoms include myelosuppression, nausea, vomiting, diarrhea, and elevated liver enzymes. Management is supportive care, including gastric lavage and symptomatic treatment.
Pregnancy & Lactation
Pregnancy: Category D. Avoid during pregnancy due to potential fetal harm. Lactation: Unknown if excreted in human milk; avoid breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date.
Availability
Hospitals, oncology pharmacies
Approval Status
FDA Approved, DGDA Approved
Patent Status
Generic available (original patent expired)
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
